Pimstone, Simon Neil — Insider Profile

Insider Profile

Pimstone, Simon Neil

$EPRX

Companies Filed At

Open-Market Buys (2yr)

$130K

Buy Value (2yr, open-market)

Mar 27, 2026

Most Recent Trade

Credibility
Score

40%

Hit Rate

-5.6%

Avg 90d Return

-6.3%

Median 90d Return

Evaluated Trades

+28.4%

Best Trade

-39.3%

Worst Trade

Hit rate and returns are based on 5 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.

Date	Company	Role	Nature	Dir.	Shares	Price	Value	Score
Mar 27, 2026	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	3,000	$9.50	$28K	60
Mar 27, 2026	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	2,500	$9.54	$24K	60
Mar 27, 2026	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	2,500	$9.39	$23K	60
Mar 27, 2026	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	2,000	$9.40	$19K	60
Mar 27, 2026	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	2,000	$9.44	$19K	60
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	10,000	$8.63	$86K	60
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	10,000	$8.63	$86K	60
Nov 14, 2025	$EPRX Eupraxia Pharmaceuticals	—	Other	Buy	25,000	$8.00	$200K	60
Sep 24, 2025	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	3,052	$5.50	$17K	60
Mar 31, 2025	$EPRX Eupraxia Pharmaceuticals	—	Expiry	Sell	43,750	$8.00	$350K	60
Mar 25, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	45,000	$5.14	$231K	60
May 13, 2024	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	45,000	$3.96	$178K	60
Jan 12, 2024	$EPRX Eupraxia Pharmaceuticals	—	Ownership Chg	Buy	4,000	$7.00	$28K	60
Jan 12, 2024	$EPRX Eupraxia Pharmaceuticals	—	Ownership Chg	Sell	4,000	$7.00	$28K	60
Aug 18, 2023	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Sell	4,000	$7.00	$28K	60
Mar 09, 2021	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	55,000	$8.00	$440K	60

Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Signal scores reflect the company's current score, not the score at time of trade.